Navigation Links
Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
Date:7/22/2009

ly-owned subsidiary of Rodman & Renshaw Capital Group, Inc. (Nasdaq: RODM), acted as sole book-running manager for the offering. In addition, Trout Capital LLC acted as financial advisor to the Company. The offering was conducted as a public offering pursuant to the Company's shelf registration statement filed with the Securities and Exchange Commission. Copies of the prospectus supplement and accompanying prospectus relating to the offering may be obtained by contacting Rodman & Renshaw, LLC at 1251 Avenue of the Americas, 20th Floor, New York, New York 10020, or by calling (212) 356-0549.

This announcement is neither an offer to sell nor a solicitation of an offer to buy any of our shares of common stock or warrants. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect the actual future results of the Company and the trading price of securities of the Company. The risks and uncertainties include the risk that the investors might not exercise their warrants, the Company might not be able to continue to raise additional capital as needed to fund its operations, the Company's intentions regarding the use of proceeds, and other risk factors listed or described from time to time in the Company's filings with the
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Nile Therapeutics, Inc. Completes $3.4 Million Private Placement
2. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
3. Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement
4. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
5. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
6. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
7. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
8. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
9. Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7
10. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
11. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Nov. 20, 2014 /CNW/ - Aequus Pharmaceuticals Inc. ... that it has closed a brokered private placement ... approximately C$3.7 million.  Cormark Securities Inc. and Clarus ... Brokered Offering for a syndicate of agents that ... Corp. (collectively the "Agents"). Concurrently with the Brokered ...
(Date:11/18/2014)... , Nov. 18, 2014 Cord Blood ... sponsor of the 10th Annual World Stem Cell Summit, the ... stakeholders. The 2014 World Stem Cell Summit will be held ... Antonio, Texas . The World ... development of lifesaving cures and therapies, convening the most prominent ...
(Date:11/18/2014)... 17, 2014 pH measurement and control ... the pharmaceutical, chemical, and food and beverage industries. But ... and how do pH sensors work? METTLER TOLEDO has ... in process industries with these questions and more. , ... in the process industries. The actual sensor, the pH ...
(Date:11/18/2014)... Atlanta, Georgia (PRWEB) November 18, 2014 ... Automotive (Melbourne, Australia) recently formed a partnership with ... University, Swinburne University of Technology, and the USDA’s ... structural components reinforced with nanocellulose. Nanocellulose is a ... The goal of the project is to replace ...
Breaking Biology Technology:Aequus Pharmaceuticals closes $4.2 million private placement financing 2Aequus Pharmaceuticals closes $4.2 million private placement financing 3Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3pH Guide from METTLER TOLEDO Explains Measurement, Theory and Practice of pH Applications 2American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 2American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 3
... McCormick School of Engineering and Applied Science at Northwestern ... of probe used in atomic force microscopy (AFM), which ... Using diamond, researchers made a much more durable ... are typically used in AFM to gather information from ...
... SEATTLE, Nov. 11 Dendreon Corporation (Nasdaq: DNDN ) ... Revenue for the third quarter of 2009 was $25,000 compared ... for the nine months ended September 30, 2009 was $80,000 ... 2008. , Dendreon,s total operating expenses for the third ...
... HAIKOU CITY, China, Nov. 11 /PRNewswire-Asia-FirstCall/ -- China Pharma,Holdings, ... specialty pharmaceutical products in China, today announced financial,results for the ... Third Quarter 2009 Financial Highlights, -- ... the, third quarter of ...
Cached Biology Technology:New nanocrystalline diamond probes overcome wear 2Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 2Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 3Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 4Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 5Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 6China Pharma Holdings, Inc. Reports Third Quarter 2009 Financial Results and Corporate Updates 2China Pharma Holdings, Inc. Reports Third Quarter 2009 Financial Results and Corporate Updates 3China Pharma Holdings, Inc. Reports Third Quarter 2009 Financial Results and Corporate Updates 4China Pharma Holdings, Inc. Reports Third Quarter 2009 Financial Results and Corporate Updates 5China Pharma Holdings, Inc. Reports Third Quarter 2009 Financial Results and Corporate Updates 6China Pharma Holdings, Inc. Reports Third Quarter 2009 Financial Results and Corporate Updates 7China Pharma Holdings, Inc. Reports Third Quarter 2009 Financial Results and Corporate Updates 8China Pharma Holdings, Inc. Reports Third Quarter 2009 Financial Results and Corporate Updates 9
(Date:11/7/2014)... associate professor, biomedical engineering, in the Grove School ... York, have identified a molecule that could lead ... aggressive forms of breast cancer. , Triple negative ... owing to aggressive proliferation and metastasis and a ... team, discovered the overexpression of intercellular adhesion molecule-1 ...
(Date:11/6/2014)... deaths occur because of metastasis, yet progress in ... slow. , "It,s been particularly challenging to design ... research fellow in systems biology at Harvard Medical ... until after they,ve already metastasized." , Gujral and ... should help researchers better understand how metastasis begins. ...
(Date:11/5/2014)... – Kelly Redmond has dedicated his career to ... to a general audience. , As deputy director ... Center at Nevada,s Desert Research Institute, Redmond has ... management, application and dissemination of climate data to ... Fall Meeting in San Francisco on December 15-19, ...
Breaking Biology News(10 mins):Migration negation 2Migration negation 3Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2
... scientists at UCLA showed for the first time that ... into electrically active motor neurons, a discovery that may ... the motor neurons derived from the iPS cells appeared ... derived from human embryonic stem cells, although further testing ...
... WASHINGTONResearchers are exploring extreme conditions for life in a ... 20 meters (66 feet) below the surface of Lake ... peculiar geological formationssinkholes made by water dissolving parts of ... typical of the huge freshwater lake are rarely to ...
... , McGill University chemistry professor Chao-Jun (C.J.) Li is ... chemistry, an entirely new approach to the science which eschews ... substances like water and new ways of making molecules. ... significant, but following the road less travelled is also paying ...
Cached Biology News:UCLA stem cells scientists make electrically active motor neurons from iPS cells 2Great Lake's sinkholes host exotic ecosystems 2Peptides-on-demand: McGill researcher's radical new green chemistry makes the impossible possible 2
... CHEMICON's In Vitro Osteogenesis Assay Kit contains ... to a mature osteoblastic lineage, as determined ... kit provides all the necessary reagents and ... standard plate reader. This product is useful ...
... ATP-Gamma-S binds to ATP-binding proteins. To ... FL fluorophore was linked through the ... its potential use for binding studies ... an important new substrate for Fhit ...
... offers precise 96 and 384-well transfers in ... and 200ul disposable tips, the 96 channel ... precision across a volume range from 1-200uls. ... positions that enable indexing into 384 well ...
... contain 60 rabbit tissue samples arrayed on Superfrost ... slides and 1 hematoxylin and eosin (H&E) stained ... different tissues from 4 rabbit organisms, for a ... tissue sample (or core) is 1.5 mm in ...
Biology Products: